Teza Capital Management LLC Invests $51,000 in Iovance Biotherapeutics, Inc. $IOVA

Teza Capital Management LLC acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,317 shares of the biotechnology company’s stock, valued at approximately $51,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Iovance Biotherapeutics in the fourth quarter worth $47,000. Accredited Investors Inc. acquired a new stake in shares of Iovance Biotherapeutics in the first quarter worth $33,000. WealthTrust Axiom LLC acquired a new stake in shares of Iovance Biotherapeutics in the first quarter worth $33,000. Flputnam Investment Management Co. acquired a new stake in shares of Iovance Biotherapeutics in the first quarter worth $37,000. Finally, Gould Asset Management LLC CA bought a new position in Iovance Biotherapeutics in the first quarter worth $39,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analysts Set New Price Targets

IOVA has been the subject of several research reports. Wells Fargo & Company reduced their target price on Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. The Goldman Sachs Group cut Iovance Biotherapeutics from a “neutral” rating to a “sell” rating in a research report on Tuesday, July 15th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Iovance Biotherapeutics in a research report on Tuesday, August 19th. Zacks Research raised Iovance Biotherapeutics to a “hold” rating in a research report on Tuesday, August 12th. Finally, UBS Group cut Iovance Biotherapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $17.00 to $2.00 in a research report on Friday, May 16th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Iovance Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $11.90.

Iovance Biotherapeutics Stock Performance

Shares of NASDAQ IOVA opened at $2.37 on Wednesday. The stock has a market cap of $857.58 million, a PE ratio of -1.93 and a beta of 0.82. The business has a fifty day moving average of $2.41 and a two-hundred day moving average of $2.72. Iovance Biotherapeutics, Inc. has a 52-week low of $1.64 and a 52-week high of $12.51.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The company had revenue of $59.95 million for the quarter, compared to the consensus estimate of $67.14 million. Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. Analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.